Eisai Formally Requests Judicial Review Of NICE Alzheimer’s Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
Grounds for review include procedural issues, irrationality and human rights, according to Eisai.
You may also be interested in...
Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time
Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.
Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time
Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.
U.K. Court Upholds NICE Guidance On Alzheimer’s Drugs
Judge finds in favor of agency in five claims brought by Eisai but directs NICE to clarify advice for people with learning disabilities and whose first language is not English.